|Bid||0.00 x 800|
|Ask||116.04 x 900|
|Day's range||110.87 - 116.30|
|52-week range||90.14 - 146.26|
|Beta (5Y monthly)||0.73|
|PE ratio (TTM)||37.31|
|Earnings date||05 May 2020|
|Forward dividend & yield||0.80 (0.71%)|
|Ex-dividend date||15 Apr 2020|
|1y target est||140.33|
Zoetis has received FDA approval for Simparica Trio, a new combination parasite preventative for dogs.
Zoetis Inc. (NYSE:ZTS) will participate in the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020, in Boston, Mass. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 2:10 p.m. ET.
Zoetis acquires Ethos Diagnostic Science, a veterinary reference lab business, to further expand its comprehensive diagnostics capabilities.
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.